Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
26/05/2026 12:39
BRIEF-Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer May 26 (Reuters) - Briacell Therapeutics Corp BCT.TO:
BRIACELL RECEIVES POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) FOR PHASE 3 STUDY IN METASTATIC BREAST CANCER
BRIACELL THERAPEUTICS CORP - DSMB RECOMMENDS CONTINUATION OF BRIACELL PHASE 3 STUDY WITH NO SAFETY CONCERNS
Source text: ID:nGNX6qxyz
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study